Applying Ultrasound to Mechanically and Noninvasively Sensitize Prostate Tumors to TRAIL‐Mediated Apoptosis

Advanced Science, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 20, 2025

Abstract Non‐surgical and safe prostate cancer (PCa) therapies are in demand. Soluble tumor necrosis factor (TNF‐α) related apoptosis inducing ligand (TRAIL), a cancer‐specific drug, shows preclinical efficacy but has short circulation half‐life. This research shown that physiological fluid shear stress activates mechanosensitive ion channels (MSCs), such as Piezo1, enhancing TRAIL‐mediated cells. Herein, noninvasive, focal ultrasound (FUS) is implemented to augment the pro‐apoptotic effects of TRAIL. Using thermally FUS parameters, it observed TRAIL sensitivity increases with higher pressure PCa cells, mediated by Piezo1. confirmed examining calcium chelation, MSC inhibitors, PIEZO knockdown. In vivo, multi‐dose study 10 min exposure 0 4‐h intervals between significantly reduce burden, an increase evident enhanced cleaved‐caspase 3 expression. mechanotherapy offers clinically translatable approach utilizing widely available technology, applicable treat additional types.

Language: Английский

Targeting novel regulated cell death: disulfidptosis in cancer immunotherapy with immune checkpoint inhibitors

Biomarker Research, Journal Year: 2025, Volume and Issue: 13(1)

Published: Feb. 26, 2025

Abstract The battle against cancer has evolved over centuries, from the early stages of surgical resection to contemporary treatments including chemotherapy, radiation, targeted therapies, and immunotherapies. Despite significant advances in treatment recent decades, these therapies remain limited by various challenges. Immune checkpoint inhibitors (ICIs), a cornerstone tumor immunotherapy, have emerged as one most promising advancements treatment. Although ICIs, such CTLA-4 PD-1/PD-L1 inhibitors, demonstrated clinical efficacy, their therapeutic impact remains suboptimal due patient-specific variability immune resistance. Cell death is fundamental process for maintaining tissue homeostasis function. Recent research highlights that combination induced regulatory cell (RCD) ICIs can substantially enhance anti-tumor responses across multiple types. In cells exhibiting high levels recombinant solute carrier family 7 member 11 (SLC7A11) protein, glucose deprivation triggers programmed (PCD) pathway characterized disulfide bond formation REDOX (reduction-oxidation) reactions, termed “disulfidptosis.” Studies suggest disulfidptosis plays critical role efficacy SLC7A11 cancers. Therefore, investigate potential synergy between this study will explore mechanisms both processes progression, with goal enhancing response targeting intracellular pathway.

Language: Английский

Combating cancer immunotherapy resistance: a nano‐medicine perspective

Cancer Communications, Journal Year: 2025, Volume and Issue: unknown

Published: April 10, 2025

Abstract Cancer immunotherapy offers renewed hope for treating this disease. However, cancer cells possess inherent mechanisms that enable them to circumvent each stage of the immune cycle, thereby evading anti‐cancer immunity and leading resistance. Various functionalized nanoparticles (NPs), modified with cationic lipids, pH‐sensitive compounds, or photosensitizers, exhibit unique physicochemical properties facilitate targeted delivery therapeutic agents tumor microenvironment (TME). These NPs are engineered modify activity. The crucial signal transduction pathways by which counteract resistance outlined, including enhancing antigen presentation, boosting activation infiltration tumor‐specific cells, inducing immunogenic cell death, counteracting immunosuppressive conditions in TME. Additionally, review summarizes current clinical trials involving NP‐based immunotherapy. Ultimately, it highlights potential nanotechnology advance

Language: Английский